Disease Progression

"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Descriptor ID	D018450
MeSH Number(s)	C23.550.291.656
Concept/Terms	Disease Progression Disease Progression Disease Progressions Progression, Disease Progressions, Disease Disease Exacerbation Disease Exacerbation

Below are MeSH descriptors whose meaning is more general than "Disease Progression".

Diseases [C]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Disease Attributes [C23.550.291]
Disease Progression [C23.550.291.656]

Below are MeSH descriptors whose meaning is related to "Disease Progression".

Below are MeSH descriptors whose meaning is more specific than "Disease Progression".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.

Bar chart showing 875 publications over 31 distinct years, with a maximum of 59 publications in 2018 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1996	0	6	6
1997	0	2	2
1998	0	5	5
1999	0	5	5
2000	0	7	7
2001	0	9	9
2002	0	9	9
2003	0	17	17
2004	0	11	11
2005	0	28	28
2006	0	24	24
2007	1	26	27
2008	0	29	29
2009	1	24	25
2010	3	34	37
2011	3	41	44
2012	3	35	38
2013	4	37	41
2014	5	50	55
2015	7	48	55
2016	6	41	47
2017	7	46	53
2018	10	49	59
2019	7	38	45
2020	8	51	59
2021	4	30	34
2022	2	27	29
2023	0	25	25
2024	13	24	37
2025	1	11	12

Below are the most recent publications written about "Disease Progression" by people in Profiles.

Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.

View in: PubMed
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed
Homer-Bouthiette C, Wilson KC. Noninvasive Ventilation in Acute Asthma Exacerbations: A Systematic Review. Ann Am Thorac Soc. 2025 May; 22(5):776-784.

View in: PubMed
Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025 May 01; 392(17):1710-1720.

View in: PubMed
Dunlay SM, Pinney SP, Lala A, Stewart GC, McIlvennan C, Wong RP, Morris AA, Pagani FD, Allen LA, Breathett K, Cogswell R, Colvin MM, Cowger JA, Drakos SG, Gelfman LP, Kanwar MK, Kiernan MS, Kittleson MM, Lewis EF, Moazami N, Ogunniyi MO, Pandey A, Rogers JG, Schumacher KR, Slaughter MS, Tedford RJ, Teuteberg J, Valantine HA, DeFilippis EM, Dixon DD, Golbus JR, Gulati G, Hanff TC, Hsiao S, Lewsey SC, McCormick AD, Nayak A, Fenton KN, Longacre LS, Shanbhag SM, Taddei-Peters WC, Stevenson LW. Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure-A Call to Action. JAMA Cardiol. 2025 Apr 01; 10(4):391-398.

View in: PubMed
Bell AJ, Ram S, Labaki WW, Murray S, Kazerooni EA, Galban S, Martinez FJ, Hatt CR, Wang JM, Ivanov V, McGettigan P, Khokhlovich E, Maiorino E, Suryadevara R, Boueiz A, Castaldi PJ, Mirkes EM, Zinovyev A, Gorban AN, Galban CJ, Han MK. Temporal Exploration of Chronic Obstructive Pulmonary Disease Phenotypes: Insights from the COPDGene and SPIROMICS Cohorts. Am J Respir Crit Care Med. 2025 Apr; 211(4):569-576.

View in: PubMed
McManus RM, Komes MP, Griep A, Santarelli F, Schwartz S, Ram?n Perea J, Schlachetzki JCM, Bouvier DS, Khalil MA, Lauterbach MA, Heinemann L, Schl?ter T, Pour MS, Lovotti M, Stahl R, Duthie F, Rodr?guez-Alc?zar JF, Schmidt SV, Spitzer J, Noori P, Maillo A, Boettcher A, Herron B, McConville J, Gomez-Cabrero D, Tegn?r J, Glass CK, Hiller K, Latz E, Heneka MT. NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression. Immunity. 2025 Feb 11; 58(2):326-343.e11.

View in: PubMed
Burnim M, Putcha N, LaFon D, Woo H, Azar A, Groenke L, Stampfli M, Schaub A, Fawzy A, Balasubramanian A, Fedarko N, Cooper CB, Bowler RP, Comellas A, Krishnan JA, Han MK, Couper D, Peters SP, Drummond MB, O'Neal W, Paine R, Criner G, Martinez FJ, Curtis JL, Barr G, Huang YJ, Woodruff P, Dransfield M, Hansel NN. Serum Immunoglobulin G Levels Are Associated with Risk for Exacerbations: An Analysis of SPIROMICS. Am J Respir Crit Care Med. 2025 Feb; 211(2):215-221.

View in: PubMed
Schneider LS, Freiesleben SD, van Breukelen G, Wang X, Brosseron F, Heneka MT, Teipel S, Kleineidam L, Stark M, Roy-Kluth N, Wagner M, Spottke A, Schmid M, Roeske S, Laske C, Munk MH, Perneczky R, Rauchmann BS, Buerger K, Janowitz D, D?zel E, Glanz W, Jessen F, Rostamzadeh A, Wiltfang J, Bartels C, Kilimann I, Schneider A, Fliessbach K, Priller J, Spruth EJ, Hellmann-Regen J, Peters O. Linking higher amyloid beta 1-38 (A?(1-38)) levels to reduced Alzheimer's disease progression risk. Alzheimers Dement. 2025 Feb; 21(2):e14545.

View in: PubMed
Kolstad J, Zoppo C, Johnston JM, D'Souza P, K?hn AL, Vardar Z, Peker A, Hader A, Celik H, Lewis CJ, Lindsay C, Rentiya ZS, Lebel C, Vedantham S, Vachha B, Gray-Edwards HL, Acosta MT, Tifft CJ, Shazeeb MS. Natural history progression of MRI brain volumetrics in type II late-infantile and juvenile GM1 gangliosidosis patients. Mol Genet Metab. 2025 Mar; 144(3):109025.

View in: PubMed

People

Explore

Similar Concepts

Top Journals